Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Global Oral Mucositis Therapeutics Report 2016 - Pipeline Review of 11 Companies/Institutions & 14 Molecules - Research and Markets

Research and Markets
Posted on: 20 Sep 16

Research and Markets has announced the addition of the "Oral Mucositis - Pipeline Review, H2 2016" report to their offering.

'Oral Mucositis - Pipeline Review, H2 2016'; Oral Mucositis pipeline therapeutics constitutes close to 14 molecules. Out of which approximately 13 molecules are developed by Companies and remaining by the Universities


Oral Mucositis Oral mucositis is the most common type of mucositis. It is a debilitating complication of cancer surgery, chemotherapy and radiation. Symptoms include change in color, hyposalivation, a change in the integrity of the mucosa and the presence of edema on the lips and/or the tongue. Treatment included oral decontamination (mouth care) and oral debridement.

'Oral Mucositis - Pipeline Review, H2 2016' outlays comprehensive information on the therapeutics under development for Oral Mucositis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews of key players involved in therapeutic development for Oral Mucositis and features dormant and discontinued projects. Currently, The molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 7, 1 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Key Topics Covered:

  1. Introduction
  2. Oral Mucositis Overview
  3. Therapeutics Development
  4. Pipeline Products for Oral Mucositis - Overview
  5. Pipeline Products for Oral Mucositis - Comparative Analysis
  6. Oral Mucositis - Therapeutics under Development by Companies
  7. Oral Mucositis - Therapeutics under Investigation by Universities/Institutes
  8. Oral Mucositis Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Oral Mucositis - Products under Development by Companies
  13. Oral Mucositis - Products under Investigation by Universities/Institutes
  14. Oral Mucositis - Companies Involved in Therapeutics Development
  • Aldeyra Therapeutics, Inc.
  • Cellceutix Corporation
  • Colby Pharmaceutical Company
  • Daewoong Pharmaceutical Co., Ltd.
  • Galera Therapeutics, Inc.
  • Onxeo SA
  • Oragenics, Inc.
  • Otsuka Holdings Co., Ltd.
  • Soligenix, Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Spherium Biomed S.L.

For more information about this report visit

Related Topics: Gastrointestinal Drugs

View source version on

Business Wire

Last updated on: 20/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.